Exciting Educational Opportunity for Pediatric Hematology/Oncology Professionals The FDA announces a new educational collaboration with the American Society of Pediatric Hematology Oncology (ASPHO) designed specifically for early career pediatric hematology/oncology clinicians and researchers. This comprehensive program addresses a critical gap in training by providing participants with foundational knowledge of pediatric hematology/oncology drug development and the regulatory review process. Understanding these complex processes is essential for advancing treatments for children with blood disorders and cancer. Program Structure: • In-person kickoff session at the 2026 ASPHO Annual Meeting in Minneapolis, MN, to be held from April 29-May 2 • Seven monthly virtual sessions (approximately 3 hours each) • Expert-led curriculum covering regulatory pathways and drug development Application Timeline: The application deadline is December 29, 2025. This FDA-ASPHO collaboration represents our continued commitment to supporting the next generation of pediatric specialists and advancing therapeutic options for children. We encourage eligible clinicians and researchers to apply for this unique learning opportunity. https://lnkd.in/efGgZniw #PediatricOncology #FDA #MedicalEducation #DrugDevelopment #ASPHO #PediatricHematology
FDA and ASPHO Launch Pediatric Hematology/Oncology Program
This title was summarized by AI from the post below.
